Characteristics and clinical outcome of T1 breast cancer: A multicenter retrospective cohort study

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 623-628

  Houvenaeghel, G ^a   Goncalves, A ^a,o   Classe, J M ^b   Garbay, J R ^c   Giard, S ^d   Charytensky, H ^e   Cohen, M ^a   Belichard, C ^f   Faure, C ^g   Uzan, S ^h   Hudry, D ⁱ   Azuar, P ^j   Villet, R ^k   Gimbergues, P ^l   Tunon de Lara, C ^m   Martino, M ^a   Lambaudie, E ^a   Coutant, C ⁱ   Dravet, F ^b   Chauvet, M P ^d   Chereau Ewald E ^a,h   Penault Llorca, F ^l   Esterni, B ^n,o   more..

^a AIX MARSEILLE UNIVERSITY   (France)

^b Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f CENTRE RENÉ HUGUENIN   (France)

^g CENTRE LÉON BÉRARD   (France)

^h HÔPITAL TENON   (France)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

^j Hôpital de Grasse   (France)

^k GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^l CENTRE JEAN PERRIN   (France)

^m INSTITUT BERGONIÉ   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Adjuvant systemic therapy; Breast cancer; Prognosis; T1N0M0

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADJUVANT SYSTEMIC THERAPY; BREAST CANCER; PROGNOSIS; T1N0M0;

ADJUVANTS, PHARMACEUTIC; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896886832     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt532     Document Type: Article

References (30)

1. Fracheboud J, Otto SJ, van Dijck JA et al. Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer 2004; 91: 861-867.
2. Bland KI, Menck HR, Scott-Conner CE et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 1998; 83: 1262-1273.
3. Leitner SP, Swern AS, Weinberger D et al. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, b N0 M0). Cancer 1995; 76: 2266-2274.
4. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and causespecific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007; 25: 4952-4960.
5. Fisher B, Dignam J, Tan-Chiu E et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93: 112-120.
6. Kennedy T, Stewart AK, Bilimoria KY et al. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol 2007; 14: 2918-2927.
7. Lee AK, Loda M, Mackarem G et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bNOMO): clinicopathologic features and outcome. Cancer 1997; 79: 761-771.
8. Hanrahan EO, Valero V, Gonzalez-Angulo AM et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): a review of the literature. J Clin Oncol 2006; 24: 2113-2122.
9. Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol 2010; 11: 1193-1199.
10. Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012; 379: 432-444.
11. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
12. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
13. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
14. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
15. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
16. Fine JG, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
17. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988; 75: 383-386.
18. Sanchez-Munoz A, Perez-Ruiz E, Jurado JM et al. Outcome of small invasive breast cancer with no axillary lymph node involvement. Breast J 2011; 17: 32-38.
19. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999; 85: 2183-2189.
20. Ichizawa N, Fukutomi T, Iwamoto E et al. Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 2002; 32: 108-109.
21. Mann GB, Port ER, Rizza C et al. Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma. Ann Surg Oncol 1999; 6: 591-598.
22. Garassino I, Gullo G, Orefice S et al. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. Breast 2009; 18: 263-266.
23. Chia SK, Speers CH, Bryce CJ et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004; 22: 1630-1637.
24. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-930.
25. Fisher B, Bryant J, Dignam JJ et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149.
26. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-5706.
27. Livi L, Meattini I, Saieva C et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 2012; 118: 3236-3243.
28. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-5699.
29. Petrelli F, Barni S. Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooledanalysis. Med Oncol 2012; 29: 2586-2593.
30. Rodrigues MJ, Peron J, Frenel JS et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol 2013; 24: 916-924.